<DOC>
	<DOCNO>NCT02680197</DOCNO>
	<brief_summary>The study design investigate efficacy safety different dos CHF5259 long act muscarinic antagonist patient moderate severe COPD .</brief_summary>
	<brief_title>Study Evaluate Efficacy/Safety 4 Doses CHF5259 Via Dry Powder Inhaler ( DPI ) Patients With COPD</brief_title>
	<detailed_description>Outpatients attend hospital clinics/study centre recruit . Patients moderate severe COPD airflow obstruction accord GOLD 2015 criterion . A total approximately 300 patient enrol . Patients follow 3 different treatment period 4 week separate 3 week wash-out period . The study last approximately 21 week patient total 11 clinic visit perform study . The primary endpoint Forced Expiratory Volume 1 second ( FEV1 ) Area Under Curve ( AUC ) 0-12h normalised time Day 28 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Male female patient age ≥ 40 year 2 . Patients diagnosis stable COPD least 12 month screen visit . 3 . Current smoker exsmoker smoke history least 10 packyears 4 . A postbronchodilator FEV1 ≥ 40 % ≤70 % predict normal value , postbronchodilator FEV1/FVC &lt; 0.7 , change FEV1 prebronchodilator value ( reversibility ) least 5 % screen 5 . Patients bronchodilator longacting muscarinic antagonist longacting 2 agonist ( monotherapy dual therapy ) , patient ICS + LABA ( longacting beta2agonist ) ICS ( Inhaled Corticosteroids ) + LAMA ( Long Acting Muscarinic Agonist ) least 4 week prior screen . ( Patients FEV1 &lt; 50 % predict value history 1 exacerbation within last 12 month must treat ICS+LABA ICS+LAMA screen ) 6 . Ability cooperative attitude understand perform require outcome measurement protocol ( e.g . spirometry manoeuvre ) ability understand risk involve . Ability train use dry powder inhaler . 1 . Diagnosis asthma respiratory disorder ( COPD ) may interfere data interpretation accord investigator 's opinion . 2 . Patients COPD exacerbation lower respiratory tract infection within 8 week prior screen , runin period , result use antibiotic , oral parenteral corticosteroid , hospitalisation . 3 . Patients history ≥ 2 exacerbation within last 12 month prior screen . 4 . Patients treat oral/parenteral β2agonists nebulised bronchodilator phosphodiesterase inhibitor receive LABA/LAMA/ICS treatment therapy 4 week prior screen runin period . 5 . Patient inhale corticosteroid initiate , effective dose change , within 4 week prior screen runin period ( patient stable dose ICS least 4 week prior screen allow ) . 6 . Patients require long term ( least 12 hour daily ) oxygen therapy chronic hypoxemia . 7 . Patients known respiratory disorder COPD include limited alpha1 antitrypsin deficiency , active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension interstitial lung disease . 8 . Patients medical diagnosis narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction opinion investigator would prevent use anticholinergic . 9 . Patients unstable concurrent disease might , judgement investigator , place patient undue risk potentially compromise result interpretation study ; 10 . Patients concomitant disease poor prognosis ( e.g. , cancer ... ) . 11 . Patients clinically significant cardiovascular condition diagnose last 6 month 12 . Patients know atrial fibrillation ( AF ) : 1 . Paroxysmal Atrial Fibrillation 2 . Persistent 3 . Long stand persistent . 4 . Permanent 13 . Patients clinically significant abnormal 12lead ECG might , judgment investigator , place patient undue risk potentially compromise result interpretation study . 14 . Patients whose electrocardiogram 12lead ECG show QTcF &gt; 450 m male QTcF &gt; 470 m female . 15 . Patients clinically significant laboratory abnormality indicate significant unstable concomitant disease might , judgement investigator , place patient undue risk potentially compromise result interpretation study . 16 . Pregnant lactate woman woman physiologically capable become pregnant ( i.e . woman childbearing potential ) UNLESS willing use highly effective birth control methods 17 . Patients know intolerance/hypersensitivity contraindication treatment M3 Antagonist excipients contain formulation use study . 18 . Patients evidence alcohol drug abuse , compliant study protocol compliant study treatment accord investigator 's judgment . 19 . Patients major surgery previous 3 month plan trial may affect patient 's compliance study procedure . 20 . Patients participate another clinical trial investigational drug 2 month precede screening .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
</DOC>